A Radical New Interpretation About the Origins of Alzheimer’s Disease

Dec 11, 2024

At Everything Retirement we’ve researched and reported on, frequently and at length, about the origins and management of Alzheimer’s disease.

Put bluntly in a recent article in The Globe and Mail, this brutal condition “is traditionally understood to be caused by the accumulation of abnormal protein in the brain. Get rid of the protein, the thinking goes, and you reduce the harm.”

As simple, and as complicated, as that.

New Research, New Hypothesis

But there’s a Toronto neurologist and medicinal chemist out there who, for the past 20 years, has been exploring an alternative explanation for the condition. His name is Dr. Donald Weaver, and he’s director of the Krembil Brain Institute at Toronto’s University Health Network.

Recently, Dr. Weaver was awarded the silver Oskar Fischer Prize, worth $400,000 USD. The prize, granted through the University of Texas at San Antonio (UTSA), is given to researchers to expand the understanding of Alzheimer’s disease, which has long confounded those seeking a cure.

Dr. Weaver’s hypothesis is that Alzheimer’s is not a neurodegenerative disease, but an autoimmune disease. As The Globe and Mail reports: “His unconventional hypothesis has now won him a major award.”

Quoting Dr. Weaver directly, the newspaper article stated: “What this gives us is external validation and external support and belief that our approach has value, and indeed, may have value leading to alternative therapeutic directions for Alzheimer’s disease.”

It has been approximately 115 years since Alzheimer’s was first documented as a disease, driven by beta amyloid, a protein.

Dr. Weaver takes a contrarian view, suggesting it’s a normal part of the innate immune system in the brain, and plays several roles, including as a messenger and as a bacteria-killer. Anything that produces an immune response, whether it’s an infection, trauma or exposure to noxious substances, triggers cells in the brain to release beta amyloid, he believes.

The problem occurs when beta amyloid mistakes healthy brain cells for bacteria, he was reported as saying. “The end result is that it – oops! – accidentally starts killing brain cells.”

Dr. Weaver’s hypothesis is not definitive, though he believes that the same immune system mechanism may also apply to other diseases, such as Parkinson’s disease or other forms of dementia.

New Ideas Can Often Lead to New Cures

The Globe and Mail story concluded with an observation from Dr. Jenny Hsieh, director of the UTSA Brain Consortium, the body awarding the prize – which included several other winners in hot pursuit of a definitive solution to a problem that has baffled experts for decades.

As Dr. Hsieh observed: “We just need people to be able to work on different ideas, and be inclusive of that, because the bottom line is all of the current approaches to Alzheimer’s disease [are] not working.”

As we age, we may spend more time thinking about our health and well-being, and what the future may look like in terms of our physical and cognitive wellness. In particular, we may wonder about the origins and management of Alzheimer’s disease—something friends, family or other loved ones may already be affected by.

Recent Posts

Aviso Weekly Market Pulse: August 24th – 28th

Market developments Equities: Global equities posted broad gains on the week, led by technology and emerging markets. The Nasdaq rose, propelled by Nvidia's blockbuster earnings and outlook that reinvigorated confidence in the AI trade. Early in the week, uncertainty...

Aviso Weekly Market Pulse: August 17th – 21st

Market developments Equities: Global equity markets broadly declined over the week, with the Nikkei 225 leading losses at ~-4%, followed by the Nasdaq and then the S&P 500 Index. Sentiment was weighed down by a combination of elevated oil prices stoking inflation...

NEI Monthly Market Insights: July 2026

Markets widen their field of vision July forced investors to look beyond the most obvious signals. The Federal Reserve held its policy rate steady, but the reaction in longer-term bond yields showed that financial conditions can change even when the overnight rate...

Aviso Weekly Market Pulse: August 10th – 14th

Market developments Equities: Global equities posted a broadly positive week, with the MSCI All Country World Index hitting a record high on Thursday, driven largely by renewed enthusiasm for the artificial intelligence trade and cooling US inflation data that reduced...

Aviso Weekly Market Pulse: July 27th – 31st

Market developments Equities: Global equities rebounded firmly as a powerful recovery in technology and semiconductor names reversed a stretch of AI-trade derating. The S&P 500 rose 1.05% and the Nasdaq 1.59%, with chipmakers posting their biggest single-day advance...

Aviso Weekly Market Pulse: July 20th – 24th

Market developments Equities: Global equity markets endured a turbulent week, with escalating Middle East conflict, surging oil prices and growing skepticism around AI investment returns as dominant themes. Tesla was among the week's most notable casualties, tumbling...